Inhibition of recombinant L-type voltage-gated calcium channels by positive allosteric modulators of GABAA receptors.
Benzodiazepines (BDZs) depress neuronal excitability via positive allosteric modulation of inhibitory GABA(A) receptors (GABA(A)R). BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels (L-VGCCs), which could contribute to reduced neuronal excitability. Because neuronal L-VGCC function is up-regulated after long-term GABA(A)R modulator exposure, an interaction with L-VGCCs may also play a role in physical dependence. The current studies assessed the effects of BDZs (diazepam, flurazepam, and desalkylflurazepam), allopregnanolone, pentobarbital, and ethanol on whole-cell Ba(2+) currents through recombinant neuronal Ca(v)1.2 and Ca(v)1.3 L-VGCCs expressed with β(3) and α(2)δ-1 in HEK293T cells. Allopregnanolone was the most potent inhibitor (IC(50), ∼10 μM), followed by BDZs (IC(50), ∼50 μM), pentobarbital (IC(50), 0.3-1 mM), and ethanol (IC(50), ∼300 mM). Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP) L-VGCC antagonists. All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only BDZs and pentobarbital induced a negative shift in Ca(v)1.2 channel inactivation. Mutation of the high-affinity DHP binding site (T1039Y and Q1043M) in Ca(v)1.2 channels reduced pentobarbital potency. Despite the structural similarity between benzothiazepines and BDZs, mutation of an amino acid important for diltiazem potency (I1150A) did not affect diazepam potency. Although L-VGCC inhibition by BDZs occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up-regulation of L-VGCCs during long-term treatment, pentobarbital and ethanol inhibited L-VGCCs at clinically relevant concentrations.
Department of Physiology and Pharmacology, University of Toledo College of Medicine, Health Science Campus, Toledo, OH 43614, USA.
Damien E
DE
Earl
Elizabeth I
EI
Tietz
D000494:Allosteric Regulation / Q000187:drug effects / Q000502:physiology; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000502:physiology; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D020746:Calcium Channels, L-Type / Q000235:genetics / Q000502:physiology*; D018757:GABA Modulators / Q000494:pharmacology*; D057809:HEK293 Cells; D006801:Humans; D051381:Rats; D011963:Receptors, GABA-A / Q000502:physiology*; D011994:Recombinant Proteins / Q000235:genetics
D002121:Calcium Channel Blockers; D020746:Calcium Channels, L-Type; D018757:GABA Modulators; C419385:L-type calcium channel alpha(1C); D011963:Receptors, GABA-A; D011994:Recombinant Proteins
Neuropsychopharmacology. 2004 Nov;29(11):1994-2006
15266351
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3239-44
9501247
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15218-23
14625373
J Physiol. 2000 Nov 15;529 Pt 1:119-30
11080256
Nature. 1983 Apr 28;302(5911):790-4
6302512
Neuropsychopharmacology. 2007 Jul;32(7):1477-89
17151597
J Neurosci. 2001 Aug 15;21(16):5944-51
11487617
Anesth Prog. 1987 Jul-Aug;34(4):128-33
3481512
Behav Pharmacol. 2007 Sep;18(5-6):447-60
17762513
J Chromatogr. 1987 Dec 25;423:251-9
3443656
Proc Natl Acad Sci U S A. 1984 Oct;81(20):6388-92
6093100
J Pharmacol Exp Ther. 2008 Dec;327(3):872-83
18812492
Neuropharmacology. 2000 Feb 14;39(4):611-20
10728882
Br J Clin Pharmacol. 1978 Jul;6(1):69-73
352377
Mol Pharmacol. 2000 Dec;58(6):1264-70
11093762
J Neurosci. 1993 Aug;13(8):3211-21
8101867
J Physiol. 1972 Dec;227(3):749-67
4405554
J Neurosci. 2005 Nov 2;25(44):10247-51
16267232
Clin Pharmacokinet. 1999 Jun;36(6):409-24
10427466
Sci Signal. 2008 Jul 15;1(28):re7
18632551
J Neurochem. 2007 Dec;103(6):2518-28
17949410
Biochem Soc Trans. 2006 Nov;34(Pt 5):903-9
17052224
Anesthesiology. 1999 Jan;90(1):197-207
9915329
J Biol Chem. 2001 Jun 22;276(25):22100-6
11285265
Proc Natl Acad Sci U S A. 1986 Aug;83(16):6213-5
2426713
Neuropharmacology. 1987 Feb-Mar;26(2-3):275-9
2438583
Br J Clin Pharmacol. 1980 Apr;9(4):333-9
6769453
Eur J Pharmacol. 2007 Nov 14;573(1-3):39-48
17651721
J Pharmacol Sci. 2006 Oct;102(2):221-30
17031067
Steroids. 2002 May;67(6):519-28
11960630
J Gen Physiol. 1985 May;85(5):621-47
2582076
Psychopharmacology (Berl). 1981;75(4):380-2
6803284
Neuron. 1991 Jul;7(1):45-57
1648941
Channels (Austin). 2008 Jul-Aug;2(4):233-51
18719397
Annu Rev Pharmacol Toxicol. 1997;37:361-96
9131258
Brain Res. 1981 Mar 23;209(1):177-88
6260300
Mol Pharmacol. 1997 May;51(5):872-81
9145926
Can J Physiol Pharmacol. 1998 Sep;76(9):909-20
10066142
Eur J Pharmacol. 1999 Jan 8;364(2-3):221-7
9932727
Br J Clin Pharmacol. 1981 Jan;11(1):35-40
6783055
J Neurophysiol. 2004 Nov;92(5):2820-30
15201306
J Biol Chem. 1996 Nov 29;271(48):30330-5
8939992
J Pharmacol Exp Ther. 1997 Aug;282(2):513-20
9262310
Brain Res. 2000 Jun 23;868(2):202-14
10854572